Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 53923: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

99 years and younger
All genders
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 43423: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

99 years and younger
All genders
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML. We would like to rely on Advarra IRB as the IRB …
Learn More

UPCC 51423 A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

99 years and younger
All genders
Please refer to Protocol Section 3. (OBJECTIVES AND ENDPOINTS). Please refer to Protocol Section 3. (OBJECTIVES AND ENDPOINTS). Please refer to Protocol Section 3. (OBJECTIVES AND ENDPOINTS).
Learn More

UPCC 49923: An Open-Label, Multicenter, Phase 1/1B Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies

99 years and younger
All genders
Please refer to Protocol Section 2 (Objectives and Endpoints). Please refer to Protocol Section 2 (Objectives and Endpoints). Please refer to Protocol Section 2 (Objectives and Endpoints).
Learn More

UPCC 51923:A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 24223: AIRPanc - A Phase 2 , Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced

99 years and younger
All genders
Please refer to Protocol Section 2 (Study Objectives). Please refer to Protocol Section 15.1 (Study Design/Endpoints). Please refer to Protocol Section 15.1 (Study Design/Endpoints).
Learn More

UPCC 13419: An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

99 years and younger
All genders
The purpose of this study is to evaluate the safety, recommended dose, antitumor activity, and pharmacokinetics of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The safety of JCAR017 in subjects who are receiving concurrent ibrutinib will also be evaluated.
Learn More

UPCC 06423 First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies

99 years and younger
All genders
Please refer to Protocol Section 3.0 Objectives and Endpoints). Please refer to Protocol Section 3.0 Objectives and Endpoints). Please refer to Protocol Section 3.0 Objectives and Endpoints).
Learn More

UPCC 31923: A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors

99 years and younger
All genders
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor tyrosine kinase inhibitor. The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as …
Learn More

UPCC 25420: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

99 years and younger
All genders
This study is available to subjects who have previously agreed to receive lisocabtagene maraleucel. The lisocabtagene maraleucel T cells for those subjects that were produced do not meet all of the prespecified release criteria to be used as a routine prescription drug as required by the governing health authority-- this …
Learn More
131 - 140 of 206